Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Lung Neoplasms 11Breast Neoplasms 11Head and Neck Neoplasms 8Neoplasms 5Neoplasm Metastasis 4NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Brain Neoplasms 3Respiratory Tract Diseases 2Neoplasms, Squamous Cell 2Carcinoma, Squamous Cell 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Pancreatic Neoplasms 1Non-Metastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma 1Lung Diseases 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFR-mutant Non-small Cell Lung Cancer × Gefitinib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡